In Chemotherapy for Lung Cancer, Sometimes Less is More

Restricted access

Eric Roeland, MD, is from the UC San Diego Moores Cancer Center in La Jolla, California.Charles Loprinzi, MD, is from the Mayo Clinic in Rochester, Minnesota.The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.Timothy J. Moynihan, MD, is from the Mayo Clinic in Rochester, Minnesota.Thomas J. Smith, MD, is from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.Jennifer Temel, MD, is from Massachusetts General Hospital, Boston, Massachusetts.This work was supported by the following United State National Institutes of Health Grant: CA124477 (PI Charles Loprinzi).
  • 1.

    MassarelliEAndreFLiuD. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer2003;39:5561.

    • Search Google Scholar
    • Export Citation
  • 2.

    ShanafeltTDLoprinziCMarksR. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?J Clin Oncol2004;22:19661974.

    • Search Google Scholar
    • Export Citation
  • 3.

    LangerCLiSSchillerJ. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance Status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol2007;25:418423.

    • Search Google Scholar
    • Export Citation
  • 4.

    RadzikowskaEGlazPRoszkowskiK. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol2002;13:10871093.

    • Search Google Scholar
    • Export Citation
  • 5.

    GridelliC. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol2004;15:419426.

    • Search Google Scholar
    • Export Citation
  • 6.

    AzzoliCGBakerSJrTeminS. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol2009;27:62516266.

    • Search Google Scholar
    • Export Citation
  • 7.

    EttingerDSAkerleyWBeplerG. Non-small cell lung cancer. J Natl Compr Canc Netw2010;8:740801.

  • 8.

    RielyGJChaftJELadanyiM. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw2011;9:13281330.

  • 9.

    EarleCC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol2003;22:315321.

  • 10.

    HoTHBarberaLSaskinR. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol2011;29:15871591.

    • Search Google Scholar
    • Export Citation
  • 11.

    MurilloJRKoellerJ. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist2006;11:10951099.

    • Search Google Scholar
    • Export Citation
  • 12.

    EmanuelEJYoung-XuYLevinskyNG. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med2003;138:639643.

  • 13.

    ConnorSRPyensonBFitchK. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage2007;33:238246.

    • Search Google Scholar
    • Export Citation
  • 14.

    SaitoALandrumMBNevilleB. The effects on survival of continuing chemotherapy to near death. BMC Palliat Care2011;10:14.

  • 15.

    TemelJSGreerJAMuzikanskyA. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med2010;363:733742.

    • Search Google Scholar
    • Export Citation
  • 16.

    ColbyWHDahlinCLantosJ. The National Consensus Project for Quality Palliative Care Clinical Practice Guidelines Domain 8: ethical and legal aspects of care. HEC Forum2010;22:117131.

    • Search Google Scholar
    • Export Citation
  • 17.

    SandlerAGrayRPerryMC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med2006;355:25422550.

    • Search Google Scholar
    • Export Citation
  • 18.

    CiuleanuTBrodowiczTZielinskiC. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet2009;374:14321440.

    • Search Google Scholar
    • Export Citation
  • 19.

    BakitasMLyonsKDHegelMT. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA2009;302:741749.

    • Search Google Scholar
    • Export Citation
  • 20.

    ConnorSRPyensonBFitchK. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage2007;33:238246.

    • Search Google Scholar
    • Export Citation
  • 21.

    GreerJAMcMahonPMTramontanoA. Effect of early palliative care on health care costs in patients with metastatic NSCLC [abstract]. J Clin Oncol2012;30(Suppl):Abstract 6004.

    • Search Google Scholar
    • Export Citation
  • 22.

    AsahinaHSekineIHorinouchiH. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer2012;13:3943.

    • Search Google Scholar
    • Export Citation
  • 23.

    MassarelliEAndreFLiuDD. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer2003;39:5561.

    • Search Google Scholar
    • Export Citation
  • 24.

    ShanafeltTDLoprinziCMarksR. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?J Clin Oncol2004;22:19661974.

    • Search Google Scholar
    • Export Citation
  • 25.

    SaitoAMLandrumMBNevilleBA. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care2011;10:14.

  • 26.

    SaitoAMLandrumMBNevilleBA. Hospice care and survival among elderly patients with lung cancer. J Palliat Med2011;14:929939.

  • 27.

    NelsonJEGayEBBermanAR. Patients rate physician communication about lung cancer. Cancer2011;117:52125220.

  • 28.

    HuskampHAKeatingNLMalinJL. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med2009;169:954962.

    • Search Google Scholar
    • Export Citation
  • 29.

    ChristakisNALamontEBSmithJL. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ2000;320:469472.

    • Search Google Scholar
    • Export Citation
  • 30.

    SteensmaDLoprinziC: The art and science of prognosis in patients with advanced cancer. Eur J Canc2000;36:20252027.

  • 31.

    PanagopoulouEPanagopoulouEPanagopoulouE. Concealment of information in clinical practice: is lying less stressful than telling the truth?J Clin Oncol2008;26:11751177.

    • Search Google Scholar
    • Export Citation
  • 32.

    KeatingNLLandrumMBRogersSOJr. Physician factors associated with discussions about end-of-life care. Cancer2010;116:9981006.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 40 40 0
PDF Downloads 9 9 0
EPUB Downloads 0 0 0